FAKTOR OPTIONSSCHEIN - IDORSIA | Market Closed - Deutsche Boerse AG 10:21:27 2024-07-11 am EDT | ||
| 1.37 EUR | +5.38% |
|
| Current month | -12.74% | ||
| 1 month | -1.44% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
IDORSIA LTD
Latest news about IDORSIA LTD
More news
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 1.37 | +5.38% |
| 24-07-10 | 1.3 | -9.09% |
| 24-07-09 | 1.43 | +2.14% |
| 24-07-08 | 1.4 | -0.71% |
| 24-07-05 | 1.41 | -4.73% |
Delayed Quote Deutsche Boerse AG
Last update July 11, 2024 at 10:21 am EDT
More quotesStatic data
| Product type | Warrant Esotici e Strutturati |
|---|---|
| Buy / Sell | CALL |
| Underlying | IDORSIA LTD |
| Issuer | 
BNP Paribas
|
| WKN | PN2P1D |
| ISIN | DE000PN2P1D8 |
| Date issued | 2021-12-10 |
| Strike | 2.208 CHF |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 50 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 999.8 € |
|---|---|
| Lowest since issue | 0.98 € |
| Spread | 0.01 € |
| Spread % | 0.72% |
Company Profile
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Sector
-
Consensus: Idorsia Ltd
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
2.132
CHF
Average target price
1.692
CHF
Spread / Average Target
-20.61%
- Stock Market
- Certificates
- Certificat
